TG Therapeutics (NASDAQ:TGTX) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of TG Therapeutics (NASDAQ:TGTX - Free Report) to a hold rating in a report released on Thursday morning, MarketBeat Ratings reports. They currently have $37.00 target price on the biopharmaceutical company's stock.

TG Therapeutics Price Performance

Shares of TGTX stock traded down $0.59 during trading hours on Thursday, hitting $37.08. 957,478 shares of the company's stock were exchanged, compared to its average volume of 2,876,739. TG Therapeutics has a 52 week low of $16.65 and a 52 week high of $46.48. The stock has a market cap of $5.89 billion, a price-to-earnings ratio of 154.50 and a beta of 1.91. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. The stock's 50-day moving average is $36.05 and its 200-day moving average is $35.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The firm's revenue was up 90.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.07) EPS. As a group, research analysts forecast that TG Therapeutics will post 0.08 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director owned 228,816 shares in the company, valued at $8,452,463.04. The trade was a 4.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TGTX. Voya Investment Management LLC lifted its stake in shares of TG Therapeutics by 9.8% during the first quarter. Voya Investment Management LLC now owns 300,453 shares of the biopharmaceutical company's stock valued at $11,847,000 after acquiring an additional 26,714 shares during the period. Cim Investment Management Inc. bought a new stake in TG Therapeutics during the 1st quarter worth about $241,000. Strs Ohio acquired a new position in TG Therapeutics during the 1st quarter valued at about $785,000. Intech Investment Management LLC boosted its stake in shares of TG Therapeutics by 20.5% in the 1st quarter. Intech Investment Management LLC now owns 86,527 shares of the biopharmaceutical company's stock valued at $3,412,000 after purchasing an additional 14,694 shares during the last quarter. Finally, Focus Partners Wealth grew its position in shares of TG Therapeutics by 4.1% during the 1st quarter. Focus Partners Wealth now owns 59,017 shares of the biopharmaceutical company's stock worth $2,327,000 after buying an additional 2,323 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.